延迟至术后第1天给予阿哌沙班而非利伐沙班可降低翻修全髋关节置换术后输血风险且不增加血栓栓塞事件
基于美国全国医疗数据库2016至2023年因无菌性翻修全髋关节置换术(rTHA)患者共5607例,比较阿哌沙班或利伐沙班在术后第0天与第1天启动预防性抗凝的血栓栓塞与出血并发症。阿哌沙班第1天启动与较低的输血和急性贫血 odds 相关,且不增加深静脉血栓和肺栓塞 odds,心肌梗死 odds 降低;利伐沙班启动时机与出血、输血或血栓栓塞并发症无显著差异。
要点
- 阿哌沙班术后第1天启动较第0天输血 odds 降低(aOR 0.702,95%CI 0.57至0.862,P=0.001)。
- 阿哌沙班术后第1天启动心肌梗死 odds 降低(aOR 0.338,95%CI 0.171至0.668,P=0.002)。
- 利伐沙班术后第0天与第1天启动在出血、输血及血栓栓塞并发症上无显著差异。
核心结论
- 翻修全髋关节置换术后第1天启动阿哌沙班与降低输血风险相关,且不增加血栓栓塞并发症风险。
- 利伐沙班的给药时机与术后出血、输血风险或血栓栓塞并发症无显著关联。
研究设计与样本
- 回顾性队列研究,使用覆盖美国约25%手术的全国医疗数据库,纳入2016至2023年因无菌性翻修全髋关节置换术(rTHA)患者共5607例。
- 阿哌沙班组2990例(53.33%),其中646例(21.61%)术后第0天启动、2344例(78.39%)术后第1天启动。
- 利伐沙班组2617例(46.67%),其中598例(22.85%)术后第0天启动、2019例(77.15%)术后第1天启动。
- 采用多变量回归分析比较队列间差异,主要结局为90天术后出血并发症(急性贫血、血肿、出血、输血)与血栓栓塞并发症(深静脉血栓、肺栓塞、卒中、心肌梗死)。
主要发现
- 与术后第0天启动相比,阿哌沙班术后第1天启动者输血 odds 较低(aOR 0.702,95%CI 0.57至0.862,P=0.001)。
- 与术后第0天启动相比,阿哌沙班术后第1天启动者急性贫血 odds 较低(aOR 0.890,95%CI 0.792至0.999,P=0.049)。
- 阿哌沙班术后第1天启动者深静脉血栓和肺栓塞 odds 与第0天启动者相似,但心肌梗死 odds 降低(aOR 0.338,95%CI 0.171至0.668,P=0.002)。
- 利伐沙班患者术后第0天与第1天启动在出血结局、输血需求或血栓栓塞并发症方面无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal timing for initiating direct oral anticoagulants for venous thromboembolism prophylaxis following revision total hip arthroplasty (rTHA) is unknown. This study compared rates of thromboembolic and bleeding complications between patients beginning prophylactic courses of apixaban or rivaroxaban on postoperative day (POD) zero versus POD one. METHODS: A national health care database including approximately 25% of all surgeries performed in the United States was used to identify patients who underwent aseptic both-component rTHA between 2016 and 2023. Patients receiving apixaban or rivaroxaban for chemoprophylaxis after rTHA on POD zero were compared to patients who received the same anticoagulant on POD one. Primary outcomes included 90-day rates of postoperative bleeding complications (acute anemia, hematoma, hemorrhage, and transfusion) and thromboembolic complications (deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction). Multivariable regression analysis was used to assess differences between cohorts. In total, 5,607 patients were identified. Of the 2,990 (53.33%) patients administered apixaban, 646 (21.61%) received anticoagulation beginning POD zero compared to 2,344 (78.39%) on POD one. Of the 2,617 (46.67%) patients given rivaroxaban, 598 (22.85%) received anticoagulation on POD zero compared to 2,019 (77.15%) on POD one. RESULTS: Patients receiving apixaban on POD one had lower odds of transfusion (adjusted odds ratio [aOR]: 0.702, 95% confidence interval [CI]: 0.57 to 0.862, P = 0.001) and acute anemia (aOR: 0.890, 95% CI: 0.792 to 0.999, P = 0.049) when compared to POD zero patients. Additionally, patients receiving apixaban on POD one were associated with similar odds of deep vein thrombosis and pulmonary embolism, but with reduced odds of an myocardial infarction (aOR: 0.338, 95% CI: 0.171 to 0.668, P = 0.002). Rivaroxaban patients demonstrated no significant differences in bleeding outcomes, transfusion requirements, or thromboembolic complications between POD zero and one administration. CONCLUSIONS: Administration of apixaban on POD one was associated with a reduced risk of transfusion without an increased risk of thromboembolic complications among patients undergoing rTHA. The timing of rivaroxaban administration was not associated with postoperative bleeding, transfusion risk, or thromboembolic complications.
引用
- Telang SS, Lim MA, Kumaran P, et al. Delayed Administration of Apixaban, but Not Rivaroxaban, Reduces Transfusion Risk Without Increasing Thromboembolic Rates Following Revision Total Hip Arthroplasty. J Arthroplasty. 2025. PMID: 41318037. doi:10.1016/j.arth.2025.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。